| A | B | C | D | E | F | |
|---|---|---|---|---|---|---|
| 1 | Main | |||||
| 2 | Brand | Elahere | ||||
| 3 | Generic | mirvetuximab soravtansine | ||||
| 4 | Pricing | $6220 20ml vial; 5mg/1ml | 100mg | |||
| 5 | Approval | Available 11/14/22 | ||||
| 6 | Indication | Ovarian cancer, 70-80% express folate receptor | ||||
| 7 | ||||||
| 8 | ||||||
| 9 | 15000 | US+EU | 60 | kg | ||
| 10 | 10500 | FRalpha | 6 | mg/kg | ||
| 11 | 8400 | market share | 360 | mg | ||
| 12 | 2520 | responders | 100 | mg/vial | ||
| 13 | 526659.84 | revenue | 3.6 | vials | ||
| 14 | 6220 | price/vial | ||||
| 15 | 22392 | price/dose | ||||
| 16 | 2 | doses/non-responder | ||||
| 17 | 44784 | 70% non-responders | ||||
| 18 | 9.333333333333334 | doses/responder | ||||
| 19 | 208992 | 30% responders |